TWINTEK (06182) issues profit warning, expecting annual performance to switch from profit to a loss of approximately 23-27 million Hong Kong dollars compared to the same period last year.
Yide Investment Holdings (06182) announced that the group expects to incur a comprehensive net loss of approximately HK$23 million to HK$27 million for the year ending March 31, 2026, compared to a comprehensive net profit of approximately HK$1.3 million for the same period in 2025. The Board of Directors believes that the main reasons for the expected reversal from a comprehensive net profit to a net loss include: (i) a decrease in contract amounts awarded for projects, resulting in reduced income for the group in the current year; (ii) additional costs incurred as several supply and installation projects enter the completion stage; and (iii) a decrease in property value due to a decline in the industrial building market.
TWINTEK (06182) announced that the Group expects to incur a net comprehensive loss of approximately HK$23 million to HK$27 million for the year ending March 31, 2026, compared to a net comprehensive profit of approximately HK$1.3 million for the same period in 2025. The Board of Directors believes that the main reasons for the expected turnaround from a net comprehensive profit to a net comprehensive loss include (among others) (i) a decrease in the contract amount granted for projects, resulting in a decrease in the Group's income for the current year; (ii) additional costs incurred as several supply and installation projects enter the completion stage; and (iii) property impairment due to the decrease in the market value of industrial buildings.
Related Articles
SIPAI HEALTH (00314) repurchased 200,000 shares at a cost of approximately HKD 240,200 on June 10th.
ALPHAMAB-B(09966): The phase III clinical study of Anituximab (KN026) as first-line treatment for HER2-positive advanced breast cancer has reached the primary endpoint.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
SIPAI HEALTH (00314) repurchased 200,000 shares at a cost of approximately HKD 240,200 on June 10th.
ALPHAMAB-B(09966): The phase III clinical study of Anituximab (KN026) as first-line treatment for HER2-positive advanced breast cancer has reached the primary endpoint.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
RECOMMEND
